D rug absorption from a solid dosage form afte r oral administration depends on the release of the drug subst:1t1ce from the drug product, the dissolution or solubilization of the drug under physiological conditions, and the penneabil ity ,lcross the gastrointestinal tract. Because of the critical nature of the first nYo of these steps, in vitro dissolution Illay be reJevanr to the prediction of in vivo performance. Based on this general consideration, in vitro dissolution tests for immediate release solid oral dosage fonns, such as tablets and capsules, are used to (I) assess d,e lot-to-Iot quality of a drug product; (2) guide development of new fomlUlationsj and (3) ensure continuing product quality and performance after certain changes, such as changes in the formulation, the manufacturing process, the site of manufacture, and the scale-up of the manufacruring process, Current knowledge about the solubili ty, permeability, dissolution, and pharmacokinetics of a drug product should be co nsidered in defi ning dissolution test specifications for the drug approval process. This know ledge should also be used to ensure continued equivalence of the product, as well as to ensure the product's sameness under certain scale-up and postapproval changes.
New drug applications (NDAs) submitted to the Food and Drug Administration (FDA) conta in bioavailability data and in vitro dissolution data, that, together with chemistry, manufacturing, and controls (CMC) data, characteri ze the quality and perfonnance of the drug prodUCT. In vitro dissolution data are generall), obmined from batches that have been used in pil'Oml clinical andlor bioavailability srudies and from other human studies conducted during product development. Acceptable bioequivalence data and com pa rable in \;tro dissolution and CMC data are required for appro",,1 of abbreviated new drug applications (ANDAs) (2 1 CFR ) 14.94). The in \;tro specifications for generic products should be established based on a dissolution profile. For new dmg applications, as well as generic drug applications, the dissolution specifications should be based on acceptable clinical, bioavailabil ity, an d/or bioequivalencc batches.
Once the specifications are esmblished in an NDI\, the dissolution specifications for batch-tobatch quality assurance are published in the United States Pharmacopeia (USP) as compendial standards, which become the official specific-ations for all subsequent IR products wid, the same active ingredients. In general, these compendial dissolution standards are single-point dissolution tests, not profiles. (IVIVC) . The solubili ty of a drug is determined by dissolving cl,e highest unit dose of the drug in 250 mL of bufTer adjusted between pH 1.0 and S.D. A drug substance is considered highly soluble wh:n the dosclsolubility volullle of solution are less than or eq u<l l to 1)0 mL. J ligh-permcabiliry drubTS arc genenl ily those With, an extent of absorption that is greater than 90% in the absence 01 documented inst:1bi li ty in the gastrointestinal tracr or those whose pemlcabi~i ry has bcen detennined experimentally. The BCS suggests that for high solubility, high penneab ili ty (c,lse I) drugs and in some in st:lJlces for high solub ili ty, low permeability (case 3) drugs, 85% dissolution in O.IN IICI in 15 minutes can ensure that the bioavailability of the drug is not limi ted by dissolution. in these cases, the ra te limiting step for drug absorption is g.lstric emptying.
continued next page
The In the case of low solubility/high penneabil ity drugs (case 2), drug dissolution may be the rate limiting step for drug absorption and an rVTVC may be expected. A dissolution profile in multiple media is recommended fo r drug products in this category. In th e case of high solubi lity/low permeability drugs (case 3), permeability is the rate controlling step and a limited TVTVC may be possible, depending on the relative rates of dissolution and intestinal transit. Drugs in case 4 (i.e., low solubility/low penneability dmgs) present significant problems for oral drug de livery. The International Conference on Ilannonisation (lCI-I) QIA guideli ne (S tabili ty "Iesting of New Drug Substances and Drug Products) has recommended that for an NDA, th ree batches (two pilot and one smallcr scale) be placed into stabi li ty testi ng. These hatches also Jllay be lIsed to set dissolution specifications when a SUItable bioequivalence relationship ex ists between these batches and both cl,e pivotal clinical trial batch and the drug product intended for the market.
SETTING DISSOLUTION SPECifiCATIONS
Th ree caragorics of dissolution test specifications for imm edia te release dmg products are described in the guidance.
• Single-poinr specifications As a rounne quality control test. (For highly soluble and rapidly dissolving drug products.)
• 1l.vo-point specifications I. For characteriz.ing the quali ty of the drug product. 2. As a rourine qua lity control test for certain types of drug products (e.g., slow dissolving or poorly wate r soluble drug product like carbamazepine).
• Dissolution profile comparison I. For .Iccepting product sameness under 5UPAC-related changes.
2. ~Io waive bioequivalence requi rements for lower strengths of a dosage fonn.
3. To support wa ive rs fot other bioequivalence requirements.
In the funlre, a two-time point approach may be llsefu l, both to characterize a drug product and to serve as quality control speci fi cation.
A. Approaches for Setting Dissolution SpecijiCiltions for a New ChellliCilI Entity
Dissolution methodology and specifications developed by a sponsor are presented in the biophannaceutics section (2 1 CFR 320.24(b)(5)), and the chemistry, manufacturing, and controls secnon (21 CFR J 14.50(d)(I)(ii)(a)) of an NDA. The dissolution characteristics of the drug product should be developed based on conside ration of the pH solubility profile and pKa of the drug substance. The drug permeabi lity or octanol/water partition coefficient measurement may be useful in selecting the dissolution methodology and specifications. The dissolution specifications are established in consultation with biopharmaceutics and CMC review sraff in the Office of Phannaceutical Science (O PS). For l\'DAs, the specifications should be based on the dissolution characteristics of batches used in pivotal clinical trials and/or in confirmatory bioavailabilicy swdies. If the formulation intended for Illarketing differs significandy frolll the drug product used in pivotal clinical trials, dissolution and bioequivalcnce resting between rhe two formu lations are recommended.
Dissolution testing should be carried out under mild test conditions, basket meUlod at 5011 00 rpm or paddle method at 5017 5 rpm, at 15-minute intervals, to generate a dissolution profile. For rapidly dissolving products, generation of an adequate profile sampling at 5-or IO-minute intervals may be necessary. For highly soluble and rapidl y dissolving drug products (BCS classcs I and 3), a single-point dissolution test specification of NIT 85% (Q=80%) in 60 mi nutes or less is sufficient as a routine quality control tcst (or barch-to-barch uniformity. For slowly dissolving or poorly water soluble drugs (BCS class 2), a two-poin t dissolution specification, one at 15 minutes to include a dissolution range (a dissolution window) and the other at a later point (30, 45, or 60 minutes) to ensure 85% dissolution, is recommended to characteri ze the qual ity of the product The product is expected to comply with dissolution specifica tions throughout its shelf life. If the dissolution characteristi cs of tile drug product cha nge with time, whether or not the specific,ltions should be altered will depend on demonstrating bioequivalence ohhe changed product to the original biobatch or pivota l batch. To ensure continuous batch-tobatch equivalence of the product after scale-uJl and postapproval changes in the marketplace, dissolution profiles should remain comparable to those of the approved biobatch or pivotal clinical trial batch(es).
B. Approaches for Setting Dissolution SpecificatiollS for Generic Products
The approaches for setting dissolution specifications for generic products fall into three categories, depending on whether an official compendial test for the drug product exists and on the nature of the dissolution test employed for ti,e reference listed drug. All appro\'ed new drug products shou ld meet current USP dissolution test requirements, if they exist The three categories are:
I. USP Drug Product Dissolution Test Available In thjs instance, the quality control dissolution test is the test described in the US!' The Division of Bioequivalence, Office of Generic Drugs, also recommends taking a dissolution profile at 15-minute intervals or less using the USP method for test and reference products (12 units each). The Division of Bioequivalence may also recommend submitting additional dissolution data when scientifically justified. Examples of this include (I) cases in which USP does not specify a dissolution test for all active drug substances of a combination product and (2) In this instance, companltive dissolution testing using test and reference products under a variety of test conditions is recolllmended. The test conditions may include different dissolution media (pH I to 6.8), addition of surfactant, and use of apparatus I and 2 with varying agitation. In all cases, profiles should be generated as previously recommended. The dissolution specifications are set based on the available bioequivalence and other data.
C. Special Cases

I. Two-Point Dissolution Test
For poorly water soluble drug products (e.g., carbamaza pine), dissolution testing at Illore than one time point for routine qua lity control is recommended to ensu re in vivo product performance. Altenliltively, a dissolution profile may be used for purposes of quality control.
Two-Tiered Dissolution Test
To more accurately refl ect the physiologic conditions of the gastrointestinal tract, two-tiered dissolution testing ill simulated gastric Auid (SGF) with and without pepsin or simulated intestinal flujd (S L F) with and without pancreatin may be employed to assess batch-to-batch product quality provided the bioeq uivalence is maintained.
Recent examples involving soft and hard gelatin capsules show a decrease in the dissolution profile over time either in SGF or in SlF without enzymes. This has been attributed to pellicle formation. ""hen the dissolution of aged or slower releasing capsules was carried out in the presence of an enzyme (pepsin in SG F or pancreatin in SIF), a significam increase in the dissolution was observed. In thjs setting, multiple dissolution media Illay be necessary to adequately assess product quality.
D. Mapping 01' Response S1I1face Metbodology
Mapping is defined as a process for determining the relationship between critical manufucruring variables (CNrV) and a response surface derived from an in vitro dissolution profile and an in vivo bioavailability data set. The CMV include changes in Ule fonnulation, process, equipment, materials, and methods for the drug product that can significantly affect in vitro dissolution (Skelly 1990 , Shah 1992 . The goal is to develop product specifications that will ensure bioequivalence of future batches prepared within the limits of acceptable dissolution specifications. Severa l experimenral designs are available to study the influence of CMV on product perfonmance. One approach to study and evaluate the mapping process includes (I) prepare two or more dosage formuJation s using eMV to study their in vitro Dissolution Techl1ologieslNOVEMBER 1997 FDA Immediate Release Guidance ... continued dissolution chara cteristics; (2) test the products with fastest ilnd slowest dissolution chanlctcristics along with the stand ard or the to be marketed dosage fann in slllali groups (e.g., 11> 11) ofhulll<l1l subjects; and (3) determine the bioal'ailability of the products and in vit ro-in vivo relationship. The products with extreme dissolution characteristics are also refe rred to as side batches (S iewert 1995) . If tile products with the extreme ran ge of dissolution chara cteristics ,1fC fou nd ro be bioequiv,llenr ro the standard or the to be marketed dosage form, future batches with di ssolution characteristics hetween these ranges should be equivalent to one another. This approach can be \,jewcd as \'e ri~'ing the limits of the dissolution specifications. Product dissolution specifications established lIsing;l mapping approach will provide lll<1xj11lum likelihood of ensuring stable qUill it}, and prod uct perforlI1;lIl CC . Depending 0 11 the number of products cva lu,ned, th e mapping study can provide information on in vi tTo-i n vivo correi.ltions and/or a ra nk orde r relationship between in vivo and in vitro data.
E. In Vivo-In Vitro C07nlati011S
For high ly w;tter soluble (BCS d asses I and 3) immediate rei e;1Se products using currently avail able excipients and m,lI1ufacruring rechnolof.,,)!, all rvrvc Illay not be possible. For poorly water soluble products, BCS d:tss 2, ;t n IVrvC m:ty be possible.
The value of dissolution as a quality control tool for predicting in vivo perfo rmance of a drug product is significantly enhanced if;111 in vitro-in vivo relationship (correlation or association) is established. The in vitro test serves as a tool to disti nguish between ;\ccept,lble and unacceptable dmg products. Acceptable products are bioeq ui\'alent, in tenns of in \'ivo performance, whereas ulu ccepmble products are not. To achieve an in vitro-in vivo co rrelation, at least three batches that differ in rhe in vivo as well ,IS the in vitro perform;lIlce should be aV:lilable. If the batches show differences in in vivo performan ce, thcn in vitro test conditi ons can be modified to correspond with the in vivo data [0 achie\'e an in vilro-in vivo correlation. If no di fference is fo und in the in vivo performance of the batches : lI1d if the in vitro performance is different, it may he possible to modify test conditions to achi eve the same di ssolution performance of the batches studied in vivo. Very often, the in vitro dissolution rest is found to be more se nsitive and discri minating than the in vivo rcst. From a quality assu rance point of view, a more discriminar.ive dissolu tion method is preferred, because the test will indi c;lte possible changes in the qua li ty of the product before in vivo perfonna nce is affected.
F. f1Ilidatioll and Verificati01l of Specificatious
Confirmation by in vivo snlciics may be needed for va lidation of an in vitro system. In th is situation, the same fonnulati on should be used but nonfarmulation CMV should be varied. l \vo batches with different in vitro profiles should be prepared (mapping approach). These product'! should then be rested in vivo. I f the twa products show different in viyo charllcteristics, then th e system is val idated. In contrast, if there is no difference in the in vi\'O performan ce, the resu lts can he interpreted as verifying the di ssolution specification limi ts as discussed under
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DISSOLUTION PROfilE COMPARISONS
Until recen tly, si ngle-point dissolution tests and specifications have been empl oyed in evaluating scale-u p and postapproval changes l such JS (I) sca le-up, (2) manufacturing site changes, (3) compon enr and composition changes, and (4) equi pment and process cha nges. A chan ged product may also be a lower strength of a pre\~ously approved drug product. In the presence of ce rtain minor changes, the single-poinr di ssolution test may be ,l(leq u<lte to ensu re unchanged product quality and performance. For morc major changes, a dissolution profi le cOIllIW'isOIl performed under identical conditions for the product before and after the chall ge(s) is recom mend ed (see SUPAC-IR). Dissolution profiles may be considered similar by vim,e of (I) OI'era ll profi le si mila rity and (2) similarity at evel)' dissoilltion sample time point. The dissolution profile comp,lrison may be ca rried out usi ng model independent or model dependent methods.
A. Model bulepeudeut Approach Usiug n Similarity Factor
A simple mod el independ ent approach uses a difference factor (fI ) and a simihlrity factor (f2) to compare di ssolution profiles (Moore 1996) . The difference lactor (f1 ) calculates the percent (%) difference between the two cun'es at each tim e point and is a measurement of the relative error between the two curves:
where n is clle numher of time points, Rt is the di ssolution va lue of the reference (precha nge) hatch at time t, and Tt is the di ssolution va lue of the test (postcha ngc) batch at tim e t.
The similarity facror (f2) is a logari thm ic reci procal square root transformation of the Stlill of squared error and is a measu rement of the similarity in the percent (%) dissolution between the two curves.
f 2 = 50 · 10gll l+( l/n)I,.!"( Rt-Tt )'I '''· 1001 A specific procedu re to dete rmine diffe rence and si milarity factors is as follows;
I. Detennin e the dissolution profile of two products (12 units each) of tile test (postcha nge) and reference (prechange) products.
2. Using th e mean di ssolution values (rom both curves at each time imerv,ll, calculate the difference facto r (fI ) and similarity factor (fl) using the above equa tions.
3. For cu rves ro be considered similar, fI values should be close to 0, and fl I'alues should be dose to 100. Generally, fI v:tlues up to 15 (0-15) and fl values greater than 50 (50-100) ensure sameness or equivalence of the two curves and, thus, of the performance of the test (postchange) :lnd reference (prech;mge) products. This model independent method is most suitahle for di ssolution profile comparison when three to four or morc dissolution time points are available. As further suggestions for the general approach, the following recommendations should also be considered:
• The dissolution measurements of the test and reference batches should be made under exactly the samc conditions. The disso lution time points for bodl the profiles shou ld be the same (e.g., 15,30,45,60 lIlinutes). The reference batch uscd should be the most recently manufactured prechange product.
• On ly one measurement should be considered after 85% dissol ution of both the products.
• To allow lise of mean data, the pcrcent coefficient of variation at the earlier time points (e.g., 15 minutes) should not be more than 20%, and at other time points should not be more than 10%.
• The mean dissolution values for Rt C:lI1 be derived either frolll (I) last prechange (reference) batch or (2) last two or 1Il0l'e consecutively m.lnufacnlred prechange hatches.
B. Model Independent Multivariate Confidence Region Procedure
In instances where within batch variation is more than 15% CV, a lllu lr.ivariatc model independent procedure is more suitable fo r dissolution profi le comparison. The following steps are suggested:
I. Determ ine the similarity limits in terlllS of multivariate statistical distance (MSD) based on interhatch differe nces in dissolution from reference (standard approvcd) batches.
Estimate the MSD between the test and reference mean dissolutions.
3. Estimate 90% confidence intet1 r al of true MSD between test and reference batches.
. . L Compare the upper lim it of the confidence interval with the similarity limit. The test batch is considered similar to the reference batch if the upper limit of the confidence imcrva l is less than or equal to the similarity limit.
C. Model Dependent Approacbes
Several mathematical models have been described in the literanlre to fit dissolution profiles. To allow application of these models to comparison of dissolution profiles, the following procedures are suggested:
I. Select the most appropriate model for the dissolution profi les from the standard, prechange, approved batches. A model with no morc than three parameters (such as linear, quadratic, logistic, probit, and \r Ve ibull models) is recolllmended.
2. Using data for the profile generated for each unit, fit the data to the most appropriate model. 3. A similarity region is set based on variation of parameters of the fitted model for test units (e.g., capsules or tablets) from the standard apprOl'ed batches.
4. Calculate the MSD in model parameters between test and reference batches. 5. Estimate the 90% confidence region of the (rue difference between the twO batches.
6. Compare the limits of the confidence region with the similarity region. If the confidence region is within the limits of the similarity region, the test batch is considered to have a similar dissolution profile to the reference batch .
DISSOLUTION AND SUPAC-IR
The SUPAC-lR guidance defines the levels of changes, recommended tests, and tiling documentation to ensure product quality and perforlIlance of reference (prechange product) with pomppl'oval changes in (I) components and composition, (2) site of manufacturing, (3) the scale of manufacturing, and (4) process and equipment changes in the manufacmring of immediate release products (FDA 1995) . Depending on the level of change and the biopharm:Iceutics classification system of the active drug substance, the SUPAC-IR guidance recommends diRe rent levels of in vitro dissolution test and/or in \'ivo bioequivalence studies. Tests vary dependi ng on therapeutic range and solubility and penneability factors of the drug substance. For formulation changes beyond those listed in the hJ1.1idancc, additional dissolution profile detenninations in several media are recolllmended. For manufacruring site changes, scale-up equipment changes, and minor process changes, only dissolution testing should be sufficiem to ensure unchanged product qua lity and performance. The SVPAC-IR guidance recommends dissolution profile comparisons for approving different Disso/ntioIlTedm%gies/NOYEM BE R 1997 fDA Immediate Release Guidance ... continued levels of changes and documenting product sameness between th e test (postchange) and reference (prechange) product. It recommends dissolution profile comparisons using a model indcpclldenr approach and the sim ilarity fuctor (/'2).
BIOWAIVERS
III addition to rOlltine quality control tests, co mpa rative disso lution tests have been used to waive bioequivalcllcc requirements (b iowa ivers) for lower strengths of a dosage (onll . For biowa ivcrs, a dissolution profile should be generated and evaluated using one of rhe methods described under Section V in this guidance, "Dissolution Profile Comparisons." Biowaivers are genera lly provided for multiple strengths after approval of a bioequivalence study performed on one strength, usi ng th e foll owing criteria:
For multiple strengths of lR products with linear kinetics, the bioequivalence stud y may be performed at the highest strength and waivers of in vivo studi es may be granted 0 11 lower strengths, based on an adequate dissolution test, provided the lower strengths are proportionately similar in composition (2 1 e FR 320.22 (d)(2)). Similar may also be interpreted to mean that the different strengths of the products are within the scope of changes pennitted under the category "Components and Composition," discussed in the SUPAC-IR guidance. In all cases, the approval of additional stTcnbrths is based on dissolution profil e comparisons between these additional strengths and the strength of the batch used in the pivotal bioequivalence study.
Appendix A
Dissolution Testing Conditions Appllratus
The most cOlllmonly employed dissolution test methods are (1) the basket method (Apparatus I) and (2) the paddle method (Apparatus 2) (Shah 1989) . The basket and cl,e paddle mecllOds are simple, robust, well standardized, and used worldwide. These methods are flexibl e enough {Q allow dissolution testing for a variety of drug products. For this reason, the official in vitro dissolution methods described in U.S. Pharmacopeia (US P), Apparatus I and Apparatus 2 should be used unless shown to be unsatisfuctory. The in vitro dissolution procedures, such as the reci procating cylinder (Apparatus 3) and a flow-cllrough cell system (Apparatus 4) described in the USP, may be considered if needed. These methodologies or oth er alternatives/modifications should be considered on the basis of their proven superiority for a particular product. Because of the dive rsity of biological and fonnulation variables and the evolving nature of understanding in this area, different experilllentalmodifications may need to be carried out to obtain a suitable in vivo correlation with in vitro release data. Dissolution methodologies and apparatus described in the USP can generally be used either with manual sampling or with automated procedures.
Dissolution Mediu1ll
Dissolution testing should be carried out under physiological conditions, if possible. This allows interpretation of dissolution data with regard to in vivo perforDisso/"/ltionTecim %giesINOVEMBER 1997 mallcc of the product. However, strict adherence to the b rastroi ntestinal environment need nor he lIsed in routine dissolution testing. The resting condi tions should be based on physicochemical characteristics of the drug substance and the envi ronmental condi tions the dosage form might be exposed to after ora l administration.
The volume of the dissolution mediulll is genera lly 500, 900, or 1000 mL. Sink conditions are desirable but nor mandatory. An aqueous medium with I'll ran ge 1.2 to 6.8 (ionic strength of buffers the same as in USP) should be used. -1 0 simulate intestinal fluid (SlF), a dissolution medium of I'll 6.8 should be emplo),ed. A higher pH should be justified on a case-by-case basis and, in general, should not exceed pH 8.0. To simulate gastric fluid (SGF), a dissolution medium of I'll 1.2 should be em plo)'ed without enzymes. The need for enz),mes in SGF and SIF should be evaluated on a casc-by-case basis and should be justified. Recent experience with gelatin ca psule products indicates the possible need for enz),mes (pepsin with SGF and pancreatin with SIF) to dissolve pellicles, if formed, to permit the dissolution of the drug. Usc of water as a dissolution medium also is discouraged beC"Juse test cond itions such as pH and surface tension can vary depending on the source of water and may change during the dissolution test itself, due to the inAuence of the active and inactive ingredients. For water insoluble or sparingly water soluble drug products, usc of a surfactant sllch as sodium lauryl sulfate is recolllmended (Shah 1989 (Shah , 1995 . The need for and the amount of the surfactant should be justified. Use of a hydro alcoholic medium is discouraged.
All dissolution tests for I R dosage fonns should be conducted at 37.0.5 ' C. The basket and paddle method Gill be used for performing dissolution tests under multimed ia conditions (e.g., the initial dissolution test can be carried out at pH 1.2 , and, after a su itable time interva l, a small amount of buffer can be added to raise pH to 6.8). Alternatively, if addition of an enzyme is desired, it can be added after initial snldi es (without enzymes). Use of Apparatus 3 allows easy change of the medium. Apparams 4 can also be adopted for a change in dissolution medium during the dissolution run.
Certain drug products and fonnulations are sensitive to dissolved air in the dissolution medium and will need deaeration. In general, ca psule dosage fomls tend to fl oat during dissolution testi ng with th e paddle method. I n such cases, it is recommended that a few turns of a wire helix (USP) around the capsule be used.
The apparatus suitabili ty tests should be carried out with a perfonnance smndard (i.e., ca librators) at least twice a year and after any significant equipment change or movement. However} a change from basket to paddle or vice versa may need recalibration. The equipment and dissolution methodology should include the product related operating instructions such as deaeration of th e dissolution mediwn and use of a wire helix for ca psules. Validation of automated procedures com pared to the manual procedures should be well documented. Validation of determinative steps in the dissolution testing process should comply with the set standards for analytical methodology.
Agitlltion
In general, mild agimtion condi tions should be maintained during dissolution testing to allow maximulll discriminating power and to detect products with poor in vivo perfonnance. Using the basket method, the common agitation (or stirring speed) is 50-100 rpm; with the paddle method, it is 50-75 rpm (Shah et aI., 1992) . Apparatus J and 4 are seldom used to assess the dissolution of immediate release drug products.
Su
T&lidotioll
Validation of the dissolution apparatus/methodology should include (I) the system suitabi lity test using calibrators; (2) deaeration, if necessary; (J) validatio n between manual and automated procedures; and (4) validation of a determinative step (i.e., analytical methods employed in quantitative analysis of dissolution samples). This should include all appropriate steps and procedures of analytical methods validation.
